Navigation Links
New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia

Six-Month Data Show Bifeprunox Maintained Stability Significantly Longer than Placebo and had a Favorable Weight and Lipid Profile Comparable with Placebo

MARIETTA, Ga. and COLLEGEVILLE, Pa., May 22, 2007 - Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), and Lundbeck A/S presented clinical study results on bifeprunox, an investigational treatment for adult patients diagnosed with schizophrenia, today at the 2007 annual meeting of the American Psychiatric Association. New analyses of six-month data in stabilized adult patients with schizophrenia from a double-blind, placebo-controlled study demonstrated that bifeprunox maintained stability vs. placebo and displayed a favorable weight and lipid profile comparable with placebo.

"Schizophrenia is a chronic, lifelong illness, and long-term management of the illness presents many challenges," comments Daniel Casey, M.D., Professor, Psychiatry and Neurology, Oregon Health and Science University. "Clinicians need new treatment options to help patients manage schizophrenia over the long term."

A synopsis of abstracts containing bifeprunox data presented at the meeting follows:

o In analyses of data from one Phase 3, six-month, randomized, double-blind, placebo-controlled study:

* Compared with placebo, bifeprunox significantly prolonged time to deterioration over six months.

* Bifeprunox patients experienced decreases in body weight and body mass index vs. placebo over six months.

* Bifeprunox patients showed favorable effects on total cholesterol, triglycerides, very low-density lipoprotein and low-density lipoprotein, comparable with placebo over a six-month period.

In these analyses, the most common side effects reported with bifeprunox (incidence of greater than or equal to 5 percent and twice the placebo rate) included nausea, vomiting, dizziness, anorexia, akathisia, dyski
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
3. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
4. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
5. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
6. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
7. UCB Presents Long-Term CImzia Data in Crohns Disease
8. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
11. CEL-SCI Presents Long-Term Cancer Survival Data With Multikine
Post Your Comments:
(Date:7/27/2015)... CTI BioPharma Corp. (NASDAQ and MTA: CTIC) ... quarter 2015 financial results on Thursday, August 6, 2015, ... the announcement, members of the management team will host ... provide a general corporate update at 4:30 p.m. EDT ... obtained as follows: Thursday, August 6 1:30 ...
(Date:7/27/2015)... and PARIS , July ...  and Sanofi have entered into a new global ... treatments in the emerging field of immuno-oncology. As part ... a programmed cell death protein 1 (PD-1) inhibitor currently ... trials in 2016 with new therapeutic candidates based on ...
(Date:7/27/2015)... and WESTLAKE VILLAGE, Calif. ... AGN ) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: ... Commission (FTC) has granted early termination of the waiting ... (HSR Act) with respect to Allergan,s pending acquisition of ... On July 6, 2015, each of Allergan ...
Breaking Medicine Technology:CTI BioPharma to Report Second Quarter 2015 Financial Results on August 6, 2015 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 3Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 4Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 5Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 6Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 7Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 2Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 3Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 4Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 5Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 6Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 7Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 9
... (Nasdaq: VOLC ) today announced its intention to ... principal amount of convertible senior notes due September 1, 2015 ... as amended (the "Securities Act"). Prior to June 1, 2015, ... conversion, holders will receive up to the principal amount of ...
... Inc. (Nasdaq: ANDS ) announced today that it ... Friday, September 17, 2010 at 8:35 a.m. EDT (5:35 a.m. ... in Boston.  Steve Worland, Ph.D., President and Chief Executive Officer ... clinical development programs. Dr. Worland will also present ...
Cached Medicine Technology:Volcano Corporation to Offer $100 Million Convertible Senior Notes Due 2015 2Volcano Corporation to Offer $100 Million Convertible Senior Notes Due 2015 3Volcano Corporation to Offer $100 Million Convertible Senior Notes Due 2015 4Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences 2
(Date:7/28/2015)... ... ... us for the 5th Annual Step for Hope 5K Run/Walk on Saturday, September ... in Carol Stream. All are welcome. , Now in its 5th year, the Step ... individuals and families affected by a brain aneurysm. , “We look forward to you ...
(Date:7/28/2015)... ... July 28, 2015 , ... Advanced Fertility Center of Texas (AFCT) ... 2010, and Dr Dozortsev , a Reproductive Laboratory Director at AFCT, was one ... was succeeded by Dr Gianpiero Palermo, who is credited with the discovery of ...
(Date:7/28/2015)... ... July 28, 2015 , ... One of ... Runner’s World Magazine, is plantar fasciitis . Zensah, the Miami-based compression brand, ... by a professional athletic trainer, the Zensah Ankle Support’s primary benefits include helping ...
(Date:7/28/2015)... ... July 28, 2015 , ... The joint ... areas such as reducing high-risk medication use and improving compliance with diabetes treatment ... patient behaviors and outcomes, this unique-in-the-industry Quality Network Program may be paving the ...
(Date:7/28/2015)... ... July 28, 2015 , ... Intellitec Solutions has been named ... ranking of Value Added Resellers of ERP Software is a look at the firms ... This honor represents the second such award in 2015 for Intellitec Solutions, following being ...
Breaking Medicine News(10 mins):Health News:5th Annual Step for Hope 5K Run/Walk Event in Carol Stream, IL to Benefit Renowned Brain Aneurysm Foundation 2Health News:Advanced Fertility Center of Texas Is Proud to Announce That Our Lab Director Has Been Re-elected as The American College of Embryology President 2Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2Health News:SCAN/Express Scripts MA Pharmacy Quality Network Program to be Featured in Upcoming AIS Webinar 2Health News:SCAN/Express Scripts MA Pharmacy Quality Network Program to be Featured in Upcoming AIS Webinar 3Health News:Intellitec Solutions Named by Accounting Today as Top 100 Value Added Reseller 2
... Telik, Inc.,(Nasdaq: TELK ) announced positive results ... (ezatiostat HCl) Tablets in,myelodysplastic syndrome (MDS) that support ... were reported at the 49th annual meeting of ... objectives of the trial were to evaluate the ...
... Researchers may be able to develop an antidepressant which ... in the brain instead of taking a less direct ... to take effect, according to a new study presented ... The antidepressant is also thought to be effective in ...
... 4 key proteins could determine if more invasive treatment is necessary, ... be possible to use a blood test to detect lung cancer, ... , Publishing in the Dec. 10 issue of the ... for four blood proteins -- CEA, RBP, SCC and AAT -- ...
... Dec. 7 California,s,stem cell agency made the ... 10 applications for research grants because of apparent ... cell program, the,Foundation for Taxpayer and Consumer Rights ... organization added that,to completely resolve the matter, the ...
... (Nasdaq: HEII ),( http://www.heii.com ) announced today that ... stock from NASDAQ Capital Market and,withdrawing its common stock ... December 6, 2007 of its intent to withdraw its ... and,anticipates that the last day of trading on the ...
... Relief Survey are in, NEW YORK, Dec. 7 ... breakups anymore. The fast-paced world we live in has,given way ... young,women, face. This trend can be seen in girls all ... some of the factors that contribute,to this new wave of ...
Cached Medicine News:Health News:Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome 2Health News:Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome 3Health News:Study shows new strategy for developing antidepressants 2Health News:Study shows new strategy for developing antidepressants 3Health News:Blood Test to Detect Lung Cancer Being Eyed 2Health News:Stem Cell Institute Correct in Rejecting Applications Over Conflicts of Interest; Institutions, Board Members Involved Must Be Identified, Consumer Advocates Say 2Health News:Stem Cell Institute Correct in Rejecting Applications Over Conflicts of Interest; Institutions, Board Members Involved Must Be Identified, Consumer Advocates Say 3Health News:HEI, Inc. Initiates Delisting and Deregistration of Its Shares on NASDAQ 2Health News:HEI, Inc. Initiates Delisting and Deregistration of Its Shares on NASDAQ 3Health News:What Stresses Teens Out 2Health News:What Stresses Teens Out 3
Synchron CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 Calci...
Iron FS Ferene for determination of iron in serum. Available with Calibrator: Trucal U and Controls: Trulab N, Trulab P. For automated systems....
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
Cholesterol/HDL Standard 50 mg/dl....
Medicine Products: